Dr Linda R. Mileshkin Plenary Session #ASCO21 #gyncsm Adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer did not improve OS or PFS.

#Immunotherapy doesn’t add benefit to chemo in patients with #ovariancancer #gyncsm #ovca Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial ascopubs.org/doi/full/10.12…

🎉 #YoungGynaeOncoWasBorn Congratulations Dr. Vicente Bebia 🇪🇸 wishing you all the best in your future endeavors 👏 #ENYGOcareer ESGO

Dr. Andrew Loblaw ASTRO Rachel Glicksman AnanthRavi Very interesting! We propose in our department in these cases a minimally invasive laparoscopic closure of the pouch of Douglas by a peritoneal suture. Carlos MG pubmed.ncbi.nlm.nih.gov/33313426/

Pocket memo based on the ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma: defin… pubmed.ncbi.nlm.nih.gov/34645685/

Join ONLINE ENYGO video session tomorrow 👇 🔸Minor and plastic reconstructive procedures in vulvar malignant and premalignant lesions 🔸 Lanner Maximilian 🇦🇹 Ilker Selcuk MD PhD 🇹🇷 Houssein EL HAJJ 🇫🇷 #ENYGOPrague2021 🇨🇿 ⏰ 09:00 am CET 🔗congress.esgo.org #ESGO2021 ESGO

«The #HPV immunisation programme has successfully almost eliminated #cervicalcancer in #women born since Sept 1, 1995»🇬🇧🙌🏼🇬🇧 #VaccinesWork The Lancet @Kreftforeningen UKCervicalCancer #GynCancer ESGO European Network of Young Gynae Oncologists @JoTrust #gyncsm OncoAlert 🔗thelancet.com/journals/lance…

Pocket Memo based on the ESGO/ESTRO/ESP #guidelines for the management of patients with #Endometrialcancer: Definition of prognostic risk groups. Full Article Available at IJGC 🔗ijgc.bmj.com/content/early/… ESGO ESTRO European Society of Pathology (ESP) Manon Daix Martina Angeles Fite

Welcome to a new IJGC initiative 👉#ThemeWeeks This week we are talking about #UrinaryDiversions‼️ To warm up🔥we encourage you to read this fantastic review by Carlos MG Stay tuned! 🔗 bit.ly/3GmYJer ESGO European Network of Young Gynae Oncologists IGCS Pedro T Ramirez SoMe4GynOnc

#Robot assisted #MIS in early #endometrial #cancer associated with #poorer #overall and #disease specific #survival than #laparoscopy 🚨 What is mechanism? 🤨 SGO IGCS ESGO OncoAlert The Society of Gynecologic Oncology of Canada sciencedirect.com/science/articl…

#Extended #pelvic #resection #surgery in #GynOnc associated with #major #postoperative #complications in 60% of #patients 🚨 SGO IGCS ESGO OncoAlert The Society of Gynecologic Oncology of Canada sciencedirect.com/science/articl…

Los 6 tipos de cáncer más asociados a hipercalcemia: 1-Células NO pequeñas (🫁) 2-Mama 3-Mieloma múltiple 4-Células escamosas (piel; cabeza y cuello) 5-Carcinoma urotelial (vejiga) 6-Ovario.

✈️ ÉXODO MÉDICO ✈️

The first live birth after #uterinetransposition has now been published by reitanribeiro!! Brilliant!! IGCS Mario M. Leitao, Jr SGO @esgo Ane Gerda Z Eriksson MD PhD EVA - Brazilian Gynecologic Oncology Group Sociedade Brasileira de Cirurgia Oncológica (SBCO) Fotopoulou/Cunnea Ovarian Cancer Research group Oliver Zivanovic IJGC Pedro T Ramirez sciencedirect.com/science/articl…

New @FIGO staging of #endometrialCancer: doi.org/10.1002/ijgo.1… ESGO IGCS OncoAlert GYN Cancer | #GYNCSM Pedro T Ramirez Mario M. Leitao, Jr Andreas Obermair René Pareja SoMe4GynOnc European Network of Young Gynae Oncologists IJGC Fellows a big change 🤯

EU #youth #unemployment in October 2023 🇪🇸28.0% 🇮🇹24.7% 🇷🇴22.3% 🇸🇪22.1% 🇵🇹20.8% 🇸🇰20.8% 🇪🇪20.7% 🇬🇷19.4% 🇱🇺19.3% 🇭🇷19.0% 🇫🇷17.7% 🇧🇪17.5% 🇨🇾17.5% 🇫🇮16.8% 🇪🇺14.8% 🇩🇰14.0% 🇱🇻13.9% 🇭🇺13.5% 🇱🇹13.3% 🇮🇪12.5% 🇧🇬12.4% 🇸🇮11.8% 🇦🇹10.5% 🇵🇱10.5% 🇳🇱8.4% 🇨🇿7.1% 🇲🇹7.0% 🇩🇪5.6% via EU_Eurostat

Maniobras de rotación visceral 👇🏻 🧵

What our society has become

#Radical #vaginal #trachelectomy- Longterm #oncologic & #fertility outcomes in women with early #CervicalCancer 📃@ bit.ly/4bEO2oj Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO European Network of Young Gynae Oncologists OncoAlert IJGC Fellows SoMe4GynOnc

✨ 2024: A Breakthrough Year in Gynecologic Oncology! ✨ With 6 new FDA-approved drugs/indications, we're entering a brighter future for patients battling gynecological malignancies. Hope is stronger than ever! 💪